三个皮匠报告
最新
报告分类 研搜
BETA
政策库
自研报告
new
入驻
搜索
您的当前位置：首页 > 行业数据 > 表7、BGB-43395与CDK4、CDK4/6抑制剂在治疗2L+ER+乳腺癌的临床数据对比（非头对头对比）
图片属性
图片格式：PNG 图片大小：312KB 图片尺寸：2221*1578
同报告图片
 / 4
表7、BGB-43395与CDK4、CDK4/6抑制剂在治疗2L+ER+乳腺癌的临床数据对比（非头对头对比）_第1页
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
表7、BGB-43395与CDK4、CDK4/6抑制剂在治疗2L+ER+乳腺癌的临床数据对比（非头对头对比）_第2页
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
表7、BGB-43395与CDK4、CDK4/6抑制剂在治疗2L+ER+乳腺癌的临床数据对比（非头对头对比）_第3页
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
表7、BGB-43395与CDK4、CDK4/6抑制剂在治疗2L+ER+乳腺癌的临床数据对比（非头对头对比）_第4页
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
表7、BGB-43395与CDK4、CDK4/6抑制剂在治疗2L+ER+乳腺癌的临床数据对比（非头对头对比）_第5页
所属报告： 百济神州-公司研究报告-临床早期差异化管线布局丰富助推长期快速发展-250723（50页）.pdf
打包全文图表

相关数据

最新数据
全行业研究报告分享下载平台
  • 0731-84720580
  • 商务合作：really158d
关于我们
更多
关于我们
三个皮匠报告微信公众号
三个皮匠报告微信小程序
扫码咨询网站充值下载问题
copyright@2008-2013 长沙景略智创信息技术有限公司版权所有        网站备案/许可证号：湘B2-20190120 | 工信部备案号：湘ICP备17000430号-2 | 公安备案号：湘公网安备43010402001071号
客服
商务合作
小程序
服务号
折叠